EichorEICHOR
Condition: Primary Igan Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Primary Igan

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope o
Phase 4 · 12 location(s) · Christian Medical College, Vellore, India · NCT06676384Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Phase 3 · 21 location(s) · Novartis Pharmaceuticals · NCT06858319A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Phase 2 · 1 location(s) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijin · NCT07305974A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
Phase 2 · 2 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07616700Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Phase 2 · 1 location(s) · Chengdu Suncadia Medicine Co., Ltd. · NCT07582133Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Phase 4 · 38 location(s) · Calliditas Therapeutics AB · NCT06712407A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Phase 3 · 1 location(s) · Chengdu Suncadia Medicine Co., Ltd. · NCT07014826A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Phase 2 · 2 location(s) · Guangdong Hengrui Pharmaceutical Co., Ltd · NCT07354932Study of Ravulizumab in Pediatric Participants With Primary IgAN
Phase 3 · 15 location(s) · Alexion Pharmaceuticals, Inc. · NCT07024563Atacicept in Multiple Glomerular Diseases
Phase 2 · 1 location(s) · Vera Therapeutics, Inc. · NCT06983028A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patient
Phase N/A · 1 location(s) · Sichuan Provincial People's Hospital · NCT06676007National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary
Phase 3 · 17 location(s) · Novartis Pharmaceuticals · NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary
Phase 3 · 6 location(s) · Novartis Pharmaceuticals · NCT07498335Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Phase 3 · 9 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07390123A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA
Phase 3 · 204 location(s) · Hoffmann-La Roche · NCT05797610PS-002 for the Treatment of IgA Nephropathy in Adults
Phase 1/Phase 2 · 10 location(s) · Purespring Therapeutics Limited · NCT07182227A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Phase 3 · 175 location(s) · Takeda · NCT06963827A Study of YKST02 in Participants With Primary IgA Nephropathy
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07498673Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
Phase N/A · 1 location(s) · Chinese PLA General Hospital · NCT07585981RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06926244Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
NA · 2 location(s) · St. Petersburg State Pavlov Medical University · NCT07074951
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.